Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma(RAZOR) | not yet recruiting | Phase 3 | 140 | Australasian Leukaemia and Lymphoma Group |
| 0 |
| Sep 30, 2026 |
| clinicaltrials |
| NCT07740941 | NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | recruiting | Phase 2 | 55 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07744152 | A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) | recruiting | Phase 1 | 137 | Boehringer IngelheimINDUSTRY | 5 | Sep 30, 2026 | clinicaltrials |
| NCT07782814 | An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool(DiTECT) | recruiting | — | 220 | Zedsen LimitedINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07829068 | Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy(INTROSPECT) | active not recruiting | N/A | 30 | University Hospital, GenevaOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07835412 | A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways | recruiting | — | 5,000 | Beijing Tiantan HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | Liping DouOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07842835 | Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China(CLIMB) | recruiting | — | 400 | Xiaohui RenOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 30, 2026 | clinicaltrials |
| NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | not yet recruiting | Phase 1 | 112 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 7 | Sep 30, 2026 | clinicaltrials |
| NCT07848360 | Traction-Assisted Versus Conventional Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors(TRACE-NET) | not yet recruiting | N/A | 66 | Pusan National University HospitalOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848568 | Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Children's Oncology GroupNETWORK | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | recruiting | — | 40 | Beijing Municipal Administration of HospitalsOTHER_GOV | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848815 | Risk-Based Lung Cancer Detection in COPD Patients(ELUCID) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848828 | Autonomic and Renal Contributions to Hypertension With ADT(ARCH) | recruiting | Phase 4 | 50 | Virginia Commonwealth UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848841 | Online Perioperative Education Program on Patient Satisfaction and Clinical Outcomes for Head and Neck Surgery | recruiting | N/A | 50 | Washington University School of MedicineOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | recruiting | Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849218 | A Study of DXC018 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 110 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849231 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms(CLARITY-101) | recruiting | Phase 1 | 250 | Damora TherapeuticsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849400 | Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery | not yet recruiting | N/A | 566 | Diansan SuOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849543 | Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study | not yet recruiting | N/A | 190 | Thomas Jefferson UniversityOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07849608 | Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer | recruiting | — | 200 | Qun ZhaoOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849660 | Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | active not recruiting | — | 170 | Eisai Inc.INDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07849712 | An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer(BEACON-OLD) | not yet recruiting | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850284 | SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850336 | Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment(PERFECT) | not yet recruiting | N/A | 56 | Bojan KovacevicOTHER | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07850453 | Vortosiran for VTE Prevention | not yet recruiting | Phase 2 | 150 | Ribocure Pharmaceuticals ABINDUSTRY | 4 | Sep 30, 2026 | clinicaltrials |
| NCT07850778 | ONS USE IN COLON CANCER(ONS COLON CA) | completed | — | 209 | Osmaniye Korkut Ata UniversityOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850791 | A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer | recruiting | Phase 2 | 38 | Haitao Zhao, MDOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | not yet recruiting | Phase 1 / Phase 2 | 192 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 30, 2026 | clinicaltrials |
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT00027326 | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | completed | Phase 2 | 17 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00496522 | Proton Beam Therapy for Chondrosarcoma | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00591383 | Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors | completed | Phase 1 | 10 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00591422 | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | completed | Phase 1 | 23 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 20 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT00924196 | Natural History Study of Patients With Neurofibromatosis Type I | active not recruiting | — | 259 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01230866 | Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer | active not recruiting | Phase 3 | 150 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01340547 | Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | recruiting | Phase 3 | 192 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 4 hours agoSource updated Sep 30, 2026source: clinicaltrials